Belite Bio Appoints New Chief Medical Officer
Ticker: BLTE · Form: 6-K · Filed: Sep 3, 2024 · CIK: 1889109
| Field | Detail |
|---|---|
| Company | Belite Bio, INC (BLTE) |
| Form Type | 6-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Belite Bio just hired a new CMO, Dr. Hendrik Scholl. Big news for their clinical strategy.
AI Summary
Belite Bio, Inc. announced on September 1, 2024, the appointment of Dr. Hendrik P. N. Scholl, MD, MA, as its new Chief Medical Officer. This appointment is detailed in a press release filed as Exhibit 99.1 with the SEC.
Why It Matters
The appointment of a new Chief Medical Officer can signal a strategic shift or increased focus on clinical development and regulatory affairs for the company's drug candidates.
Risk Assessment
Risk Level: low — This filing is an informational update regarding an executive appointment and does not contain significant financial or operational changes.
Key Players & Entities
- Belite Bio, Inc. (company) — Company filing the report
- Hendrik P. N. Scholl, MD, MA (person) — Newly appointed Chief Medical Officer
- September 1, 2024 (date) — Date of the press release and appointment
- Exhibit 99.1 (document) — Press release attached to the filing
FAQ
Who has Belite Bio, Inc. appointed as its Chief Medical Officer?
Belite Bio, Inc. has appointed Dr. Hendrik P. N. Scholl, MD, MA, as its Chief Medical Officer.
When was the appointment of the new Chief Medical Officer announced?
The appointment was announced on September 1, 2024.
What is the exact title of the new executive appointed by Belite Bio?
The exact title is Chief Medical Officer.
Where can the press release announcing this appointment be found?
The press release is attached to the Form 6-K filing as Exhibit 99.1.
What type of SEC filing is this report?
This report is a Form 6-K, a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Stats: 257 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-09-03 08:00:10
Filing Documents
- tm2422767d1_6k.htm (6-K) — 9KB
- tm2422767d1_ex99-1.htm (EX-99.1) — 10KB
- tm2422767d1_ex99-1img001.jpg (GRAPHIC) — 12KB
- 0001104659-24-096020.txt ( ) — 37KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15b-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-41359 Belite Bio, Inc (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant´s name into English) 12750 High Bluff Drive Suite 475, San Diego, CA 92130 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F On September 1, 2024, Belite Bio, Inc issued a press release entitled “Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit 99.1 — Press Release SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Belite Bio, Inc By: /s/ Yu-Hsin Lin Name: Yu-Hsin Lin Title: Chief Executive Officer and Chairman Date: September 3, 2024